Molecular Imaging in Alzheimer Disease: The Future is Promising

In this discussion, Dr Tanenbaum, Ana Franceschi, MD, associate professor of radiology at Lenox Hill Hospital, Hofstra/Northwell in New York City; and Adam Samchuck, senior product manager for PET Solutions at Siemens Healthineers, North America, explore the evolving role of molecular imaging in Alzheimer disease (AD) diagnosis, as well as the impact of emerging AD therapeutics.

Creators and Guests

Host

Lawrence Tanenbaum, MD, FACR

Dr. Tanenbaum is a long term collaborator with the medical imaging industry, with interests in developing applications of contrast agents, MR, CT and advanced rendering in the clinical practice of medicine focusing on efficiency, radiation dose appropriateness and physiologic imaging. Dr. Tanenbaum has authored approximately 100 scholarly and peer reviewed articles, continues to chair educational and academic meetings and has delivered over 1500 invited lectures around the world.

AS

Guest

Adam Samchuck

Guest

Ana Franceschi, MD

Professionally, I am highly motivated and dedicated to making significant contributions to advancing Neuroradiology research and practice. Specifically, I have developed a special focus on neurological molecular imaging, with an emphasis on the advancement of brain PET/MRI and hybrid imaging techniques in dementia and neurodegenerative disease.

What is Trends in Alzheimer Imaging & Management?

Moderated by Lawrence Tanenbaum, MD, FACR, Applied Radiology hosted a series of conversations with experts in Alzheimer disease imaging and management at the 2024 Radiological Society of North America Annual Meeting and Scientific Exhibition.